En utvecklingsplatform för matrixbaserad läkemedelsleverans
Tidsperiod: 2015-01-01 till 2018-12-31
Projektledare: Jöns Hilborn
Budget: 3 640 000 SEK
In this project we will establish and develop synthetic methods to construct in vivo targeting biomaterials using motives from, or extracellular matrix (ECM) components as macromolecular building blocs and to demonstrate its feasibility in animal models for at least two clinically relevant applications e.g. osteoporosis and cancer. It will start from successful preliminary data of targeting, cellular uptake and extensive experience in chemical modification of ECM components. The project has three major components (1) develop and apply bioconjugation strategies to produce ECM macromolecular structures designed to target specific sites in vivo, (2) evaluate the efficacy of these structures in cell culture systems and also to perform mechanistical studies, and (3) establish fluorescent probe techniques allowing for direct visualisation of biodistribution and targeting in vivo with special emphasis of NIR probes for deep tissues. The outcomes of this project are as follows: (i) methods allowing the bottom-up engineering of ECM based targeting materials, (ii) novel targeting approaches demonstrated in animal models for aiming to treat osteoporosis and cancers expressing specific receptors, and (iii) a methodology allowing rapid iterations over in vitro and in vivo evaluation to drastically reduce the development time for new targeting materials.